While the H12N1 Swine Flu continues to spread in the UK the government continues floundering in it’s response. There appears to be complete confusion on the issue of Tamiflu, the antiviral drug used to “treat the flu.”  Chief Medical Officer Sir Liam Donaldson appears ready to distribute vouchers to anyone off the Internet or otherwise, just days after giving doctors permission to not prescribe Tamiflu if their phone rings too much.

Because patients must be treated with 48 hours after the onset of symptoms there is limited usefulness for the drug. It also does not cure the flu, it only shortens the duration by 1-2 days. While some projections are that widespread distribution of Tamiflu to the general population would save millions of lives, the reality is no one knows if Tamiflu would be effective at all  with this type of distribution. It is more likely to create widespread resistance and render Tamiflu a useless drug.  Tamiflu is a tremendous asset for a pandemic but it should be reserved for susceptible populations and specific situations and remain under the control of doctors, not the government. Isolation and preventative measures are our front line defense against the pandemic, not handing out Tamiflu to everyone.

A case in point is the Air Force Academy outbreak of Swine Flu. It is early and Tamiflu could be administered to the entire population since they live in close quarters and could be sequestered short term in the contained environment of the Academy. Or they could be more conservative and administer Tamiflu to anyone with a history of respiratory or immune problems making them a higher risk for serious complications, and restrict the campus short term. Letting everyone in Colorado Springs have a free voucher for Tamiflu would be irresponsible.

Tamiflu is not a panacea and using it as one will probably render it useless for the people who need it most. Lets hope the UK does not create a resitant strain of flu via massive distribution of vouchers.

Summary of Situation

Updated June 11, 2009, 12:30 PM ET

A Pandemic Is Declared

On June 11, 2009, theWorld Health Organization raised the worldwide pandemic alert level to Phase 6 in response to the ongoing global spread of the novel influenza A (H1N1) virus. A Phase 6 designation indicates that a global pandemic is underway.

More than 70 countries are now reporting cases of human infection with novel H1N1 flu. This number has been increasing over the past few weeks, but many of the cases reportedly had links to travel or were localized outbreaks without community spread. The WHO designation of a pandemic alert Phase 6 reflects the fact that there are now ongoing community level outbreaks in multiple parts of world.

WHO’s decision to raise the pandemic alert level to Phase 6 is a reflection of the spread of the virus, not the severity of illness caused by the virus. It’s uncertain at this time how serious or severe this novel H1N1 pandemic will be in terms of how many people infected will develop serious complications or die from novel H1N1 infection. Experience with this virus so far is limited and influenza is unpredictable. However, because novel H1N1 is a new virus, many people may have little or no immunity against it, and illness may be more severe and widespread as a result. In addition, currently there is no vaccine to protect against novel H1N1 virus.

In the United States, most people who have become ill with the newly declared pandemic virus have recovered without requiring medical treatment, however, CDC anticipates that there will be more cases, more hospitalizations and more deaths associated with this pandemic in the coming days and weeks. In addition, this virus could cause significant illness with associated hospitalizations and deaths in the fall and winter during the U.S. influenza season.

Background

Novel influenza A (H1N1) is a new flu virus of swine origin that first caused illness in Mexico and the United States in March and April, 2009. It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread, mainly through the coughs and sneezes of people who are sick with the virus, but it may also be spread by touching infected objects and then touching your nose or mouth. Novel H1N1 infection has been reported to cause a wide range of flu-like symptoms, including fever, cough, sore throat, body aches, headache, chills and fatigue. In addition, many people also have reported nausea, vomiting and/or diarrhea.

The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency and has been actively and aggressively implementing the nation’s pandemic response plan.

Since the outbreak was first detected, an increasing number of U.S. states have reported cases of novel H1N1 influenza with associated hospitalizations and deaths. By June 3, 2009, all 50 states in the United States and the District of Columbia and Puerto Rico were reporting cases of novel H1N1 infection. While nationwide U.S. influenza surveillance systems indicate that overall influenza activity is decreasing in the country at this time, novel H1N1 outbreaks are ongoing in parts of the U.S., in some cases with intense activity.
CDC is continuing to watch the situation carefully, to support the public health response and to gather information about this virus and its characteristics. The Southern Hemisphere is just beginning its influenza season and the experience there may provide valuable clues about what may occur in the Northern Hemisphere this fall and winter.

 

CDC Response

CDC continues to take aggressive action to respond to the outbreak. CDC’s response goals are to reduce the spread and severity of illness, and to provide information to help health care providers, public health officials and the public address the challenges posed by this new public health threat.

CDC is issuing updated interim guidance in response to the rapidly evolving situation.

Clinician Guidance

CDC has issued interim guidance for clinicians on  identifying and caring for pateints with novel H1N1, in addition to providing interim guidance on the use of antiviral drugs. Influenza antiviral drugs are prescription medicines (pills, liquid or an inhaled powder) with activity against influenza viruses, including novel influenza H1N1 viruses. The priority use for influenza antiviral drugs during this outbreak is to treat people hospitalized with influenza illness, and to treat people at increased risk of severe illness, including pregnant women, young children, and people with chronic health conditions like asthma, diabetes and other metabolic diseases, heart or lung disease, kidney disease, weakened immune systems, and persons with neurologic or neuromuscular disease.

U.S. Human Cases of H1N1 Flu Infection
(As of May 2, 2009, 11:00 AM ET) States # of
laboratory
confirmed
cases Deaths
Arizona 4
California 24
Colorado 2
Connecticut 1
Delaware 4
Florida 2
Illinois 3
Indiana 3
Kansas 2
Kentucky* 1
Massachusetts 8
Michigan 2
Minnesota 1
Missouri 1
Nevada 1
New Jersey 7
New York 50
Ohio 1
South Carolina 13
Texas 28 1
Virginia 2
TOTAL (21) 160 cases 1 death

The outbreak of disease in people caused by a new influenza virus of swine origin continues to grow in the United States and internationally. Today, CDC reports additional confirmed human infections, hospitalizations and the nation’s first fatality from this outbreak. The more recent illnesses and the reported death suggest that a pattern of more severe illness associated with this virus may be emerging in the U.S. Most people will not have immunity to this new virus and, as it continues to spread, more cases, more hospitalizations and more deaths are expected in the coming days and weeks.

CDC has implemented its emergency response. The agency’s goals are to reduce transmission and illness severity, and provide information to help health care providers, public health officials and the public address the challenges posed by the new virus.